Pfizer Ltd. (NSE: PFIZER, BSE: 500680) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹17,811 Cr, it ranks #393 by market cap among the 6,197 Indian listed companies on FinBizNet, and #7 of 63 in Pharmaceuticals. At ₹3,857.00 (as of 16 Nov 2026), the share price is 26.6% below its 52-week high of ₹5,257.00 and 7.5% above its 52-week low of ₹3,589.00. The share price is down 24.2% over one year and down 22.9% over three months.
| Current Price | ₹3,857.00 |
|---|---|
| Market Cap | ₹17,811 Cr |
| NSE Symbol | PFIZER |
| BSE Code | 500680 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 24.5 |
| Return on Equity | 17.16% |
| Return on Assets | 10.77% |
| 52-Week Range | ₹3,589.00 – ₹5,257.00 |
| 1-Year Price Change | -24.2% |
| 3-Month Price Change | -22.9% |
| Beta (1Y) | 0.26 |
| Dividend Yield | 1.94% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.pfizerltd.co.in |
| Revenue | ₹727 Cr |
|---|---|
| Net Profit | ₹313 Cr |
| Net Margin | 43.1% |
| EPS (Basic) | ₹68.47 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Pfizer Ltd. reported revenue of ₹727 Cr in Q2 FY27, up 13.2% from ₹642 Cr in Q2 FY26 and up 11.3% from ₹653 Cr in Q1 FY27. It posted a net profit of ₹313 Cr for the quarter, against a net profit of ₹189 Cr in Q2 FY26 (up 65.7%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹603 Cr (Q1 FY26) to ₹727 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹727 Cr | ₹313 Cr | 43.1% |
| Q1 FY27 | ₹653 Cr | ₹204 Cr | 31.3% |
| Q4 FY26 | ₹629 Cr | ₹200 Cr | 31.8% |
| Q3 FY26 | ₹645 Cr | ₹142 Cr | 22.0% |
| Q2 FY26 | ₹642 Cr | ₹189 Cr | 29.4% |
| Q1 FY26 | ₹603 Cr | ₹192 Cr | 31.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 63.92% of Pfizer Ltd.'s shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 51.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
1. Pharmaceuticals-This segment provides various pharmaceutical products. It offers products in various therapeutic areas, including women healthcare, respiratory, multivitamins, cardiovascular, vaccines, and anti-infective. 2. Animal Health-0 3. Segment Adjustment-This segment focuses on animal health, dairy, and poultry businesses. 4. Services-This segment conducts clinical trials, new product development, and undertakes data management for drug development.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Pfizer Ltd. is trading at ₹3,857.00, with a market capitalisation of ₹17,811 Cr.
Pfizer Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Pfizer Ltd. has a P/E of 24.5 and a return on equity of 17.16%.
Pfizer Ltd. is listed on the NSE under the symbol PFIZER and on the BSE under the scrip code 500680.
Pfizer Ltd.'s share price is down 24.2% over one year and down 22.9% over three months. Its 52-week range is ₹3,589.00 to ₹5,257.00.
In Q2 FY27, Pfizer Ltd. reported revenue of ₹727 Cr and net profit of ₹313 Cr, with basic EPS of ₹68.47 (standalone, parsed from the company's exchange filing).
Pfizer Ltd. reported revenue of ₹727 Cr in Q2 FY27, up 13.2% from ₹642 Cr in Q2 FY26 and up 11.3% from ₹653 Cr in Q1 FY27.
Promoters held 63.92% of Pfizer Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.